Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J STD AIDS. 2004 Jan;15(1):17-20.

5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy.

Author information

  • 1Centro Malattie a Trasmissione Sessuale, Istituto di Scienze Dermatologiche, IRCCS Ospedale Maggiore Milano, Via Pace 9, 20122 Milan, Italy. centromts@policlinico.mi.it

Abstract

The efficacy of imiquimod in the treatment of external genital warts in HIV positive subjects was compared to a group of patients with normal immune function. Imiquimod 5% cream was applied by patients three times a week until resolution for a maximum of 16 weeks. Assessment for response and the occurrence of side effects was performed every four weeks. Thirty-one per cent of 75 HIV positive patients achieved a complete clearance, a partial response was obtained in 24% of subjects while in 45% we observed no clinical response. In the control group a total clearance was obtained in 62% of subjects, a partial response in 24% and no response in 14%. Recurrences occurred in 4/23 HIV patients and 2/31 immunocompetent patients within three months of follow-up. Side effects were minor to moderate. We conclude that imiquimod 5% cream has an acceptable efficacy and safety on HIV patients.

PMID:
14769165
DOI:
10.1258/095646204322637191
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center